Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

2.480 +0.060 (+2.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 236,946
Open 2.450
Bid (Size) 2.390 (1)
Ask (Size) 2.470 (1)
Prev. Close 2.420
Today's Range 2.330 - 2.520
52wk Range 1.730 - 8.960
Shares Outstanding 46,736,830
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire

Performance

YTD
+23.38%
+23.38%
1 Month
-17.88%
-17.88%
3 Month
+37.78%
+37.78%
6 Month
-20.51%
-20.51%
1 Year
-71.16%
-71.16%

More News

Read More
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Personalis's Return On Capital Employed Insights
Via Benzinga
Earnings Outlook For Personalis
Via Benzinga
Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce
Via Benzinga
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2023
Via Benzinga
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
Why Personalis Shares Are Trading Higher Today
Via Benzinga
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
From Personalis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.